Financial Data and Key Metrics Changes - Q3 2023 revenue reached $16.3 million, an 8% increase from $15.1 million in Q3 2022, marking a record third quarter for the company [5][21] - Gross margin decreased slightly from 62.4% in Q3 2022 to 60% in Q3 2023, attributed to solution and channel partner mix [21] - Net loss for Q3 2023 was $2.9 million, or $0.17 per share, compared to a net loss of $3.5 million in the same period in 2022 [22] - Adjusted EBITDA for Q3 2023 was $9.9 million, effectively flat year-over-year [22] - Operating cash flow was positive at $1.5 million for the quarter, with cash and short-term investments totaling $63.5 million as of September 30, 2023 [23] Business Line Data and Key Metrics Changes - The company reported 16 total RWD deals for the year, exceeding the original expectation of approximately 10 deals, indicating strong client adoption [6] - Average revenue for the top 20 pharmaceutical manufacturers was $2.1 million, with a net revenue retention rate improving to 93% from 89% in Q2 2023 [26][27] - Medicx, acquired for $95 million, is expected to enhance the company's revenue streams, particularly in patient marketing [24][15] Market Data and Key Metrics Changes - The company is experiencing a normalization of macro headwinds that had previously impacted the industry, leading to improved client engagement and investment [8][44] - The acquisition of Medicx is anticipated to expand the company's omnichannel reach beyond HCPs to patients, enhancing marketing capabilities [14][15] Company Strategy and Development Direction - The company is focused on enhancing its Dynamic Audience Activation Platform (DAAP) to integrate AI capabilities, improving pharmaceutical marketing solutions [10][11] - The acquisition of Medicx is seen as a strategic move to unlock value for customers and expand market opportunities, with expectations of significant revenue growth [19][120] - The company aims to maintain a strong focus on the top 20 pharmaceutical manufacturers while also exploring opportunities in the broader market [111] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's momentum heading into 2024, citing a positive response from clients and a strong renewal rate [8][12] - The company anticipates revenue for 2023 to be between $68 million and $70 million, with preliminary guidance for 2024 set at a minimum of $110 million [6][25] - Management noted that the recent enhancements and acquisitions position the company well to address challenges faced by clients in the healthcare system [118][120] Other Important Information - The company has completed over half of its planned cost reductions, with full benefits expected to be realized in 2024 [19][72] - The Medicx acquisition is expected to be accretive to earnings, contributing to revenue growth and profitability [120] Q&A Session All Questions and Answers Question: Can you share expected revenue contribution from Medicx for 2024? - Management indicated it is too early to provide specific figures but expressed confidence in the integration and growth potential [31][35] Question: What is the average size of new deals? - The average deal size remains in the $1 million to $2 million range, with expectations for growth as the company scales its offerings [36][37] Question: What drove the better-than-expected results in Q3? - The outperformance was attributed to the successful implementation of DAAP and increased client engagement [41][42] Question: How are clients responding to the competitive landscape? - Clients are returning after experimenting with other vendors, primarily due to the company's proven ROI and effective measurement capabilities [53][54] Question: How does the Medicx acquisition impact decision-making at the brand level? - The decision-making process involves both HCP and patient marketing leads, with the company now positioned to engage both sides effectively [60][70] Question: What is the expected impact of cost-cutting measures in 2024? - Cost reductions are expected to be fully realized in 2024, contributing to improved adjusted EBITDA margins [72]

OptimizeRx Corporation. (NASDAQ:OPRX) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Edward Stelmakh - Chief Financial and Operating Officer Stephen Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D’Silva - Senior Vice President, Corporate Finance Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Eric Martinuzzi - Lake Street Operato ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2023 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation ...

OptimizeRx Corporation (NASDAQ:OPRX) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D’Silva - Senior Vice President, Corporate Finance Conference Call Participants Jared Haase - William Blair Sean Dodge - RBC Stephanie Davis - SVB David Grossman - Stifel Neil Chatterji - B. R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to ________ Commission file number: 001-38543 OptimizeRx Corporation | (Exact name of registrant as specified in its charter) | | | --- | --- | | Nevada | 26-1265381 | | (State or ...

OptimizeRx Corporation (NASDAQ:OPRX) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Will Febbo - CEO Ed Stelmakh - CFO and COO Steve Silvestro - Chief Commercial Officer Conference Call Participants Ryan Daniels - William Blair Sean Dodge - RBC Capital Markets Stephanie Davis - SVB David Grossman - Stifel Neil Chatterji - B. Riley Eric Martinuzzi - Lake Street Operator Good afternoon everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2022 Earnings Discussio ...

Technology Solutions For Life Sciences at the Point-of-Care Corporate Presentation Physician Awareness Digital Therapy Initiation Patient Adherence Our Mission At OptimizeRx ― we are building a more informed and empowered healthcare community by developing new technology solutions that help people start and stay on life-impacting therapies. Growth Leaders | Growth Drivers EXPERIENCE 20+ Leading Health Services and Financial Businesses `) Med Panel Will Febbo Chief Executive Officer Ed Stelmakh Chief Financi ...

OptimizeRx Corporation (NASDAQ:OPRX) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Will Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial and Operating Officer Steve Silvestro - Chief Commercial Officer Marion Odence-Ford - General Counsel and Chief Compliance Officer Andrew D’Silva - Senior Vice President, Corporate Finance Conference Call Participants Jared Haase - William Blair Sean Dodge - RBC Capital Markets David Grossman - Stifel Joy Zhang - SVB Securit ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 ☐ Transition Report pursuant to 13 or 15(d) of the Securities Exchange Act of 1934 FORM 10-Q ☒ Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 For the transition period from __________ to __________ Commission File Number: 001-38543 OptimizeRx Corporation (Exact name of registrant as specified in its charter) Nevada 26-1265381 (State or other jurisdi ...